Trial Profile
Treatment of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Lutetium-177-DOTA-EB-TATE (Primary) ; Lutetium-(177Lu)-oxodotreotide
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 Jun 2023 According to a Molecular Targeting Technologies Media Release, data from this study were published in Clinical Nuclear Medicine.
- 21 Jun 2023 Results (n=10) presented in a Molecular Targeting Technologies Media Release.
- 19 Jun 2023 According to a Molecular Targeting Technologies Media Release, the results from this trial were published in the Theranostics.